Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC

Article

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with blond wavy hair in front of a dark blue background
Related Content
Icon of a breast with various clinicians using medical equipment

Personalizing CDK4/6 Inhibitor Care to Reduce Adverse Events

Bridget Hoyt
August 22nd 2025
Article
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
August 22nd 2025
Podcast
Image of a breast with tumor

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

Bridget Hoyt
August 22nd 2025
Article
The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
August 22nd 2025
Podcast
graphic of a person with breast tumors

JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

Chris Ryan
August 22nd 2025
Article
Graphic of a person with a breast tumor

Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

Bridget Hoyt
August 22nd 2025
Article